Literature DB >> 20300788

Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.

Jorunn Stamnaes1, Siri Dorum, Burkhard Fleckenstein, Daniel Aeschlimann, Ludvig M Sollid.   

Abstract

Transglutaminase 2 (TG2) is well characterized as the main autoantigen of celiac disease. The ability of TG2 to deamidate and crosslink gluten peptides is essential for the gluten-dependent production of TG2 specific autoantibodies. In patients with primarily extraintestinal manifestation of gluten sensitivity the repertoire of autoantibodies may be different. In dermatitis herpetiformis (DH), TG3 appears to be the target autoantigen whereas in gluten ataxia (GA) autoantibodies reactive with TG6 are present. A functional role for TG3 and TG6 in these diseases has yet to be described. It is also not known whether these enzymes can use gluten peptides implicated in the pathology as substrates. We here report that similar to TG2, TG3 and TG6 can specifically deamidate gluten T cell epitopes. However, the fine specificities of the enzymes were found to differ. TG2 can form covalent complexes with gluten by iso-peptide and thioester bonds. We found that both TG3 and TG6 were able to complex with gluten peptides through thioester linkage although less efficiently than TG2, whereas TG6 but not TG3 was able to form iso-peptide linked complexes. Our findings lend credence to the notion that TG3 and TG6 are involved in the gluten-induced autoimmune responses of DH and GA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300788     DOI: 10.1007/s00726-010-0554-y

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  26 in total

1.  Celiac disease: a challenge for all physicians.

Authors:  Srihari Mahadov; Peter H R Green
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

2.  The many faces of celiac disease.

Authors:  Vivian Asamoah; Ranier von Coelln; Joseph Savitt; Linda A Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

Review 3.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

Review 4.  Clinical and diagnostic aspects of gluten related disorders.

Authors:  Francesco Tovoli; Chiara Masi; Elena Guidetti; Giulia Negrini; Paola Paterini; Luigi Bolondi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

5.  Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.

Authors:  T Rauhavirta; S-W Qiao; Z Jiang; E Myrsky; J Loponen; I R Korponay-Szabó; H Salovaara; J A Garcia-Horsman; J Venäläinen; P T Männistö; R Collighan; A Mongeot; M Griffin; M Mäki; K Kaukinen; K Lindfors
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

Review 6.  Celiac disease: a model disease for gene-environment interaction.

Authors:  Raivo Uibo; Zhigang Tian; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

7.  The prostate-specific protein, transglutaminase 4 (TG4), is an autoantigen associated with male subfertility.

Authors:  Siiri E Iismaa
Journal:  Ann Transl Med       Date:  2016-10

8.  Physio-pathological roles of transglutaminase-catalyzed reactions.

Authors:  Mariangela Ricotta; Maura Iannuzzi; Giulia De Vivo; Vittorio Gentile
Journal:  World J Biol Chem       Date:  2010-05-26

9.  Gluten-sensitive enteropathy coincides with decreased capability of intestinal T cells to secrete IL-17 and IL-22 in a macaque model for celiac disease.

Authors:  Huanbin Xu; Stephanie L Feely; Xiaolei Wang; David X Liu; Juan T Borda; Jason Dufour; Weiwei Li; Pyone P Aye; Gaby G Doxiadis; Chaitan Khosla; Ronald S Veazey; Karol Sestak
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

10.  Hispanic Spinocerebellar Ataxia Type 35 (SCA35) with a Novel Frameshift Mutation.

Authors:  Chih-Chun Lin; Shi-Rui Gan; Deepak Gupta; Armin Alaedini; Peter H Green; Sheng-Han Kuo
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.